natgillin/translations-raw huggingface dataset:
Nogle patienter har fået taget blodprøver eller har symptomer, som viser, at deres hepatitis er forværret, efter de er holdt op med at tage emtricitabin eller tenofovirdisoproxilfumarat (to af de tre aktive stoffer i Atripla).
Some patients have had blood tests or symptoms indicating that their hepatitis has got worse after stopping emtricitabine or tenofovir disoproxil fumarate (two of the three components of Atripla).
Nogle patienter har haft følgende bivirkninger, mens de har taget Icandra og insulin:
Some patients have had the following side effects while taking Icandra and insulin:
Nogle patienter har haft symptomer eller blodprøver, der tydede på, at deres leverbetændelse (hepatitis) var blevet forværret, efter at de var holdt op med Hepsera- behandlingen.
Some patients have had symptoms or blood tests indicating that their hepatitis has worsened after stopping treatment with Hepsera.
Nogle patienter har oplevet allergiske reaktioner lige efter indsprøjtningen i form af vejrtrækningsbesvær, hævelse af ansigtet, udslæt og brystsmerter (hyppigheden er sjælden).
Some patients may have experienced allergic reactions soon after injection, consisting of breathlessness, swelling of the face, rash and chest pain (frequency is rare).
Nogle patienter har oplevet diarré, kvalme, øget luftafgang fra tarmen, forstoppelse, mavesmerter eller opkastning, når de er startet med at tage sitagliptin og metformin sammen (hyppighed: almindelig).
Some patients have experienced diarrhoea, nausea, flatulence, constipation, stomach ache or vomiting when starting the combination of sitagliptin and metformin together (frequency is common)..
Nogle patienter har oplevet et hjertetilfælde, et slagtilfælde eller et ”mini-slagtilfælde”, mens de har fået CIAMBRA, sædvanligvis i kombination med anden kræftbehandling
Some patients have experienced a heart attack, stroke or “mini-stroke” while receiving CIAMBRA usually in combination with another anticancer therapy.
Nogle patienter har oplevet et hjertetilfælde, et slagtilfælde eller et ”mini-slagtilfælde”, mens de har fået pemetrexed, sædvanligvis i kombination med anden kræftbehandling.
Some patients have experienced a heart attack, stroke or “mini-stroke” while receiving pemetrexed usually in combination with another anticancer therapy
Nogle patienter har oplevet et hjertetilfælde, et slagtilfælde eller et ”mini-slagtilfælde”, mens de har fået Permetrexed Fresenius Kabi, sædvanligvis i kombination med anden kræftbehandling.
Some patients have experienced a heart attack, stroke or “mini-stroke” while receiving Pemetrexed Fresenius Kabi usually in combination with another anticancer therapy.
Nogle patienter har oplevet følgende bivirkninger, mens de har taget Eucreas og et sulfonylurinstof:
Some patients have experienced the following side effects while taking Eucreas and a sulphonylurea:
Nogle patienter har oplevet følgende bivirkninger, mens de har taget Eucreas:
Some patients have experienced the following side effects while taking Eucreas:
Nogle patienter har oplevet følgende bivirkninger, mens de har taget Icandra og et sulfonylurinstof:
Some patients have experienced the following side effects while taking Icandra and a sulphonylurea:
Nogle patienter har oplevet følgende bivirkninger, mens de har taget Icandra:
Some patients have experienced the following side effects while taking Icandra:
Nogle patienter har oplevet følgende bivirkninger, mens de har taget Zomarist og et sulfonylurinstof:
Some patients have experienced the following side effects while taking Zomarist and a sulphonylurea:
Nogle patienter har oplevet følgende bivirkninger, mens de har taget Zomarist:
Some patients have experienced the following side effects while taking Zomarist:
Nogle patienter har oplevet følgende bivirkninger, mens de tager Jentadueto sammen med insulin
Some patients have experienced the following side effects while taking Jentadueto with insulin
Nogle patienter har oplevet følgende bivirkninger, mens de tog Jalra og et glitazon:
Some patients have had the following side effects while taking Jalra and a glitazone:
Nogle patienter har oplevet følgende bivirkninger, mens de tog Jalra og et sulfonylurinstof:
Some patients have had the following side effects while taking Jalra and a sulphonylurea:
Nogle patienter har oplevet følgende bivirkninger, mens de tog Jalra og metformin:
Some patients have had the following side effects while taking Jalra and metformin:
Nogle patienter har oplevet følgende bivirkninger, mens de tog Jalra, metformin og et sulfonylurinstof:
Some patients have had the following side effects while taking Jalra, metformin and a sulphonylurea:
Nogle patienter har oplevet følgende bivirkninger, mens de tog Xiliarx alene:
Some patients have had the following side effects while taking Xiliarx alone:
Nogle patienter har oplevet følgende bivirkninger, mens de tog Xiliarx og et glitazon:
Some patients have had the following side effects while taking Xiliarx and a glitazone:
Nogle patienter har oplevet følgende bivirkninger, mens de tog Xiliarx og et sulfonylurinstof:
Some patients have had the following side effects while taking Xiliarx and a sulphonylurea:
Nogle patienter har oplevet følgende bivirkninger, mens de tog Xiliarx og metformin:
Some patients have had the following side effects while taking Xiliarx and metformin:
Nogle patienter har oplevet følgende bivirkninger, når de har taget Efficib sammen med insulin: Meget almindelig: Lavt blodsukker
Some patients have experienced the following side effects while taking this medicine in combination with insulin:
Nogle patienter har oplevet følgende bivirkninger, når de har taget metformin alene:
Some patients have experienced the following side effects while taking metformin alone:
Nogle patienter har oplevet følgende bivirkninger, når de har taget Ristfor sammen med insulin: Meget almindelig: Lavt blodsukker
Some patients have experienced the following side effects while taking this medicine in combination with insulin:
Nogle patienter har oplevet følgende bivirkninger, når de har taget sitaglæiptin sammen med et sulfonylurinstof og metformin:
Some patients have experienced the following side effects while taking sitagliptin in combination with a sulphonylurea and metformin:
Nogle patienter har oplevet følgende bivirkninger, når de har taget Trajenta uden anden medicin:
Some patients have had the following side effects while taking Trajenta alone:
Nogle patienter har oplevet følgende bivirkninger, når de har taget Velmetia sammen med insulin: Meget almindelig: Lavt blodsukker
Some patients have experienced the following side effects while taking this medicine in combination with insulin:
Nogle patienter har oplevet følgende bivirkninger:
Some patients have had the following side effects while taking Jentadueto:
Nogle patienter har oplevet reaktioner som f.eks. hovedpine, feber, kvalme og opkastninger to dage efter hver af de første to injektioner.
Some patients had reactions including headache, fever, nausea and vomiting within two days of each of the first two injections.
Nogle patienter i behandling med Benepali, har udviklet hudkræft.
Some patients receiving Benepali have developed skin cancers.
Nogle patienter kan desuden kaste op.
In addition some patients may experience vomiting.
Nogle patienter kan dog opleve alvorlige bivirkninger, som kan kræ ve behandling.
However some patients may experience serious side effects and may require treatment.
Nogle patienter kan en gang imellem hoste kortvarig lige efter inhalation af medicinen.
Some people may occasionally cough briefly soon after inhaling the medicine.
Nogle patienter kan en gang imellem hoste kortvarig lige efter inhalation af medicinen.
Some people occasionally cough briefly soon after inhaling a medicine.
Nogle patienter kan en gang imellem hoste kortvarigt lige efter inhalation af medicinen.
Some people occasionally cough briefly soon after inhaling a medicine.
Nogle patienter kan få alvorlige bivirkninger, der kan kræve omgående behandling.
Some patients may have serious side effects that may need urgent treatment.
Nogle patienter kan have nytte af at starte behandlingen med 20 mg to gange daglig i to uger før stigning til den anbefalede dosering på 40 mg to gange daglig.
Some patients may benefit from starting treatment at a dose of 20 mg twice daily for two weeks before increasing to the recommended dose of 40 mg twice daily.
Nogle patienter kan opleve en mild, sød eller let bitter smag, afhængigt af patienten, når lægemidlet indåndes.
Some patients may experience a mild sweet or slightly bitter taste, depending on the patient, when inhaling the medicinal product.
Nogle patienter kan udvikle antistoffer (udvikles af kroppen for at bekæmpe et fremmed protein) mod kollagenet i medicinen.
Some patients may develop antibodies (made by your body to fight a foreign protein) against the collagen in the medicine.
Nogle patienter kan udvikle antistoffer over for INCRELEX.
Some patients may develop antibodies to INCRELEX.
Nogle patienter kan udvikle faktor VIII-inhibitorer, dvs. antistoffer (proteiner), som kroppens immunsystem producerer mod faktor VIII, og som kan være årsag til, at lægemidlet holder op med at virke, hvilket medfører manglende kontrol med blødninger.
Some patients may develop factor VIII inhibitors, which are antibodies (proteins) that the body’s immune system produces against factor VIII and which can cause the medicine to stop working resulting in a loss of bleeding control.
Nogle patienter med typisk atrieflagren var inkluderet i ACT II og ACT III, og BRINAVESS blev ikke fundet effektivt til konvertering af atrieflagren.
Some patients with typical atrial flutter were included in ACT II and ACT III and BRINAVESS was not found to be effective in converting atrial flutter.
Nogle patienter med årelang type 2- diabetes og hjertesygdom eller tidligere slagtilfælde, som er blevet behandlet med pioglitazon og insulin, oplevede hjertesvigt.
Some patients with long- standing type 2 diabetes mellitus and heart disease or previous stroke, who were treated with pioglitazone and insulin, experienced the development of heart failure.
Nogle patienter med årelang type 2-diabetes mellitus og hjertesygdom eller tidligere slagtilfælde, der var i behandling med pioglitazon (oral antidiabetika, der anvendes til behandling af type 2 diabetes mellitus) og insulin, udviklede hjertesvigt.
Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with pioglitazone (oral anti-diabetic medicine used to treat type 2 diabetes mellitus) and insulin experienced the development of heart failure.
Nogle patienter med årelang type 2-diabetes mellitus og hjertesygdom eller tidligere slagtilfælde, der var i behandling med pioglitazon (oral antidiabetika, der anvendes til behandling af type 2 diabetes) og insulin, udviklede hjertesvigt.
Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with pioglitazone (oral anti-diabetic medicine used to treat type 2 diabetes mellitus) and insulin experienced the development of heart failure.
Nogle patienter med årelang type 2-diabetes mellitus og hjertesygdom eller tidligere slagtilfælde, og som blev behandlet med pioglitazon og insulin, udviklede hjertesvigt.
Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with pioglitazone and insulin experienced the development of heart failure.
Nogle patienter med årelang type 2-diabetes og hjertesygdom eller tidligere slagtilfælde, som er blevet behandlet med pioglitazon og insulin, oplevede hjertesvigt.
Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke, who were treated with pioglitazone and insulin, experienced the development of heart failure.
Nogle patienter med årelang type 2-diabetes og hjertesygdom eller tidligere slagtilfælde, som er blevet behandlet med pioglitazon og insulin, oplevede hjertesvigt.
Some patients with long–standing type 2 diabetes and heart disease or previous stroke who were treated with pioglitazone and insulin experienced the development of heart failure.
Nogle patienter oplever, at deres rødme vender tilbage og er værre, end den var første gang.
Some patients experience the return of their redness worse than it was initially.
Nogle patienter, der er blevet behandlet med golimumab, har udviklet visse former for hudkræft.
Some patients treated with golimumab have developed certain kinds of skin cancer.
Nogle patienter, der er blevet behandlet med infliximab, har udviklet visse former for hudkræ ft.
Some patients treated with infliximab have developed certain kinds of skin cancer.
Nogle patienter, der er blevet behandlet med infliximab, har udviklet visse former for hudkræft.
Some patients treated with infliximab have developed certain kinds of skin cancer.
Nogle patienter, der er i behandling med Tracleer, har unormale leverfunktions- værdier.
Some patients taking Tracleer were found to have abnormal liver function tests.
Nogle patienter, der i begyndelsen af undersøgelsen slet ikke kunne læse nogen bogstaver på tavlen ("off chart"), kunne desuden ved synsprøven efter behandlingen læse mindst én linje, og også dette blev anset for klinisk vigtigt.
Furthermore, some patients who were classified as ‘off chart’ (unable to read any letters on the chart) at the beginning of the study were able to read at least one line during the eye test after treatment, and this was also considered clinically important.
Nogle patienter, der tager Lamivudin Teva Pharma B.V. eller andre kombinationsbehandlinger mod hiv, har større risiko for at få alvorlige bivirkninger end andre.
Some people taking Lamivudine Teva Pharma B.V. or other combination treatments for HIV are more at risk of serious side effects.
Nogle patienter, der tager Mekinist i kombination med dabrafenib, bemærker muligvis også, at der er opstået nye melanomer.
Some people taking Mekinist in combination with dabrafenib also may notice that new melanomas have appeared.
Nogle patienter, der tillige fik insulin, har oplevet følgende bivirkninger:
Some patients have had the following side effects while taking Trajenta and insulin:
Nogle patienter, der tillige fik metformin og et sulfonylurinstof, har oplevet følgende bivirkninger:
Some patients have had the following side effects while taking Trajenta, metformin and a sulphonylurea:
Nogle patienter, der tillige fik metformin, har oplevet følgende bivirkninger:
Some patients have had the following side effects while taking Trajenta and metformin:
Nogle patienter, især dem som er disponeret for nephrolithiasis, kan have en øget risiko for nyrestensdannelse og dermed forbundne tegn og symptomer såsom nyrekolik og nyre- eller flankesmerter.
Some patients, especially those with a predisposition to nephrolithiasis, may be at increased risk for renal stone formation and associated signs and symptoms such as renal colic, renal pain or flank pain.
Nogle patienter, som er i behandling med antiretroviral kombinationsterapi, dvs. flere typer hiv- medicin samtidig, kan udvikle knoglesygdommen osteonekrose, hvor knoglevævet går til grunde på grund af manglende blodforsyning til knoglen.
Some patients taking combination antiretroviral therapy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone).
Nogle patienter, som er i behandling med en alfa-blokker til behandling af højt blodtryk eller vand- ladningsbesvær ved forstørret prostata, kan opleve svimmelhed eller uklarhed, som skyldes lavt blodtryk, når man hurtigt sætter sig ned eller rejser sig op.
Some patients who take alpha-blocker therapy for the treatment of high blood pressure or prostate enlargement may experience dizziness or light-headedness, which may be caused by low blood pressure upon sitting or standing up quickly.
Nogle patienter, som har blodplader, der ligger på et stabilt niveau, kan selv indgive lægemidlet, når de er blevet behørigt instrueret heri.
Some patients whose platelet levels have stabilised may be able to inject the medicine themselves after they have been properly trained.
Nogle patienter, som har fået TNF-blokerende behandling, herunder Flixabi, har udviklet en sjæ lden kræ ftform kaldet hepatosplenisk T-celle-lymfom.
Some patients who have received TNF-blockers, including Flixabi have developed a rare type of cancer called Hepatosplenic T-cell Lymphoma.
Nogle patienter, som har fået TNF-blokerende behandling, herunder Remicade, har udviklet en sjælden kræftform kaldet hepatosplenisk T-celle-lymfom.
Some patients who have received TNF-blockers, including Remicade have developed a rare type of cancer called Hepatosplenic T-cell Lymphoma.
Nogle patienter, som har fået TNF-blokerende behandling, herunder Remsima, har udviklet en sjælden kræftform kaldet hepatosplenisk T-celle-lymfom.
Some patients who have received TNF-blockers, including Remsima have developed a rare type of cancer called Hepatosplenic T-cell Lymphoma.
Nogle patienter, som har fået TNF-blokkere, herunder Inflectra, har udviklet en sjælden kræftform kaldet hepatosplenisk T-celle-lymfom.
Some patients who have received TNF-blockers, including Inflectra have developed a rare type of cancer called Hepatosplenic T-cell Lymphoma.
Nogle patienter, som har oplevet et fald i respons, kan nyde gavn af en øget dosishyppighed af Entyvio 300 mg hver 4. uge.
Some patients who have experienced a decrease in their response may benefit from an increase in dosing frequency to Entyvio 300 mg every four weeks.
Nogle patienter, som oplever en nedgang i deres respons, kan have fordel af en stigning i doseringshyppighed til 40 mg Humira hver uge.
Some patients who experience decrease in their response may benefit from an increase in dosing frequency to 40 mg Humira every week.
Nogle patienter, som oplever utilstrækkeligt respons, kan have fordel af hyppigere dosering med 20 mg Humira hver uge.
Some subjects who experience insufficient response may benefit from an increase in dosing frequency to 20 mg Humira every week.
Nogle patienter, som oplever utilstrækkeligt respons, kan have fordel af hyppigere dosering med 40 mg Humira hver uge.
Some subjects who experience insufficient response may benefit from an increase in dosing frequency to 40 mg Humira every week.
Nogle patienter, som oplever, at deres respons bliver dårligere, kan have fordel af hyppigere dosering med 40 mg Humira hver uge.
Some patients who experience decrease in their response may benefit from an increase in dosing frequency to 40 mg Humira every week.
Nogle patienter, som oplever, at deres respons bliver dårligere, kan have fordel hyppigere dosering med 40 mg Humira hver uge.
Some patients who experience decrease in their response may benefit from an increase in dosing frequency to 40 mg Humira every week.
Nogle patienter, som oplever,at deres respons bliver dårligere, kan have fordel af hyppigere dosering med til 40 mg Humira hver uge.
Some patients who experience decrease in their response may benefit from an increase in dosing frequency to 40 mg Humira every week.
Nogle patienter, som pludselig holdt op med at tage ARICLAIM, fik symptomer som: svimmelhed, prikkende følelse som når noget sover eller følelse af elektriske stød (især i hovedet), søvnforstyrrelse (livagtige drømme, mareridt, søvnløshed), træthed, søvnighed, rastløshed eller uro, angst, kvalme eller opkastning, rystelser (tremor), hovedpine, muskelsmerter, irritation, diaré, forøget tendens til at svede eller svimmelhed.
Some patients who stop taking ARICLAIM suddenly have had symptoms such as: dizziness, tingling feelings like pins and needles or electric shock-like feelings (particularly in the head), sleep disturbances (vivid dreams, nightmares, inability to sleep), fatigue, sleepiness, feeling restless or agitated, feeling anxious, feeling sick (nausea) or being sick (vomiting), shaking (tremor), headaches, muscle pain, feeling irritable, diarrhoea, excessive sweating or vertigo.
Nogle patienter, som pludselig holdt op med at tage Cymbalta, oplevede symptomer som: svimmelhed, prikkende følelse som når noget sover eller følelse af elektriske stød (især i hovedet), søvnforstyrrelser (livagtige drømme, mareridt, søvnløshed), træthed, søvnighed, rastløshed eller uro, angst, kvalme eller opkastning, rystelser (tremor), hovedpine, muskelsmerter, irritation, diarré, forøget tendens til at svede eller svimmelhed.
Some patients who stop taking Cymbalta suddenly have had symptoms such as: dizziness, tingling feelings like pins and needles or electric shock-like feelings (particularly in the head), sleep disturbances (vivid dreams, nightmares, inability to sleep), fatigue, sleepiness, feeling restless or agitated, feeling anxious, feeling sick (nausea) or being sick (vomiting), shaking (tremor), headaches, muscle pain, feeling irritable, diarrhoea, excessive sweating or vertigo.
Nogle patienter, som pludselig holdt op med at tage DULOXETIN BOEHRINGER INGELHEIM, oplevede symptomer som: svimmelhed, prikkende følelse som når noget sover, søvnforstyrrelse (livagtige drømme, mareridt, søvnløshed), rastløshed eller uro, angst, kvalme eller opkastning, rystelser, hovedpine, irritation, diaré, forøget tendens til at svede eller svimmelhed.
Some patients who stop taking DULOXETINE BOEHRINGER INGELHEIM suddenly have had symptoms such as : dizziness, tingling feelings like pins and needles, sleep disturbances (vivid dreams, nightmares, inability to sleep), feeling restless or agitated, feeling anxious, feeling sick (nausea) or being sick (vomiting), tremor (shakiness), headaches, feeling irritable, diarrhoea, excessive sweating or vertigo.
Nogle patienter, som pludselig holdt op med at tage Duloxetin Lilly, oplevede symptomer som: svimmelhed, prikkende følelse som når noget sover eller følelse af elektriske stød (især i hovedet), søvnforstyrrelser (livagtige drømme, mareridt, søvnløshed), træthed, søvnighed, rastløshed eller uro, angst, kvalme eller opkastning, rystelser (tremor), hovedpine, muskelsmerter, irritation, diarré, forøget tendens til at svede eller svimmelhed.
Some patients who stop taking Duloxetine Lilly suddenly have had symptoms such as: dizziness, tingling feelings like pins and needles or electric shock-like feelings (particularly in the head), sleep disturbances (vivid dreams, nightmares, inability to sleep), fatigue, sleepiness, feeling restless or agitated, feeling anxious, feeling sick (nausea) or being sick (vomiting), shaking (tremor), headaches, muscle pain, feeling irritable, diarrhoea, excessive sweating or vertigo.
Nogle patienter, som pludselig holdt op med at tage Duloxetine Mylan, oplevede symptomer som: svimmelhed, prikkende følelse som når noget sover eller følelse af elektriske stød (især i hovedet), søvnforstyrrelser (livagtige drømme, mareridt, søvnløshed), træthed, søvnighed, rastløshed eller uro, angst, kvalme eller opkastning, rystelser (tremor), hovedpine, muskelsmerter, irritation, diarré, forøget tendens til at svede eller svimmelhed.
Some patients who stop taking Duloxetine Mylan suddenly have had symptoms such as: dizziness, tingling feelings like pins and needles or electric shock like feelings (particularly in the head), sleep disturbances (vivid dreams, nightmares, inability to sleep), fatigue, sleepiness, feeling restless or agitated, feeling anxious, feeling sick (nausea) or being sick (vomiting), shaking (tremor), headaches, muscle pain, feeling irritable, diarrhoea, excessive sweating or vertigo.